Skip to main content
Top
Published in: European Journal of Epidemiology 4/2013

01-04-2013 | DIABETES MELLITUS

Serum cystatin C and prediabetes in non-obese US adults

Authors: Charumathi Sabanayagam, Tien Yin Wong, Jie Xiao, Anoop Shankar

Published in: European Journal of Epidemiology | Issue 4/2013

Login to get access

Abstract

Diabetes mellitus is the leading cause of end stage renal disease. Cystatin C, a marker of early renal impairment has been shown to be associated with diabetes. However, it is not clear if cystatin C is associated with prediabetes, an early stage in the hyperglycemic continuum where prevention efforts have been shown to be effective in delaying or preventing the onset of diabetes. We examined 2,033 participants from the National Health and Nutrition Examination Survey 1999–2002, aged ≥20 years (female 47.2 %) who were free of diabetes mellitus, chronic kidney disease and with body mass index <30 kg/m2. Prediabetes (n = 541) was defined as a 2-h glucose concentration of 140–199 mg/dL, or a fasting glucose concentration of 110–125 mg/dL, or an A1C value of 5.7–6.4 %. Cystatin C levels were categorized into gender-specific quartiles for analysis. Elevated levels of serum cystatin C were associated with prediabetes after adjusting for potential confounders including serum total cholesterol, systolic blood pressure, body mass index and C-reactive protein. Compared to those with cystatin C in the lowest quartile, the multivariable odds ratio (95 % confidence interval) of prediabetes among those in the highest quartile was 2.08 (1.09–3.97), p for trend = 0.02. Although, this association was stronger among women and non-Hispanic whites, there was no significant interaction by sex (p = 0.1) or by race-ethnicity (p = 0.6). Our findings suggest that elevated levels of serum cystatin C are associated with prediabetes in a nationally representative sample of non-obese US adults.
Literature
1.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
2.
go back to reference Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436–40.PubMedCrossRef Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436–40.PubMedCrossRef
3.
go back to reference Mussap M, Dalla VM, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453–61.PubMedCrossRef Mussap M, Dalla VM, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453–61.PubMedCrossRef
4.
go back to reference Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29–34.PubMedCrossRef Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29–34.PubMedCrossRef
5.
go back to reference Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.PubMedCrossRef Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.PubMedCrossRef
6.
go back to reference Willems D, Wolff F, Mekahli F, Gillet C. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem. 2009;42:108–10.PubMedCrossRef Willems D, Wolff F, Mekahli F, Gillet C. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem. 2009;42:108–10.PubMedCrossRef
7.
go back to reference Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54:1335–40.PubMedCrossRef Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54:1335–40.PubMedCrossRef
8.
go back to reference American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33 Suppl 1:S11–61. American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care. 2010;33 Suppl 1:S11–61.
9.
go back to reference Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–94.PubMedCrossRef Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–94.PubMedCrossRef
10.
go back to reference Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007;30:1724–9.PubMedCrossRef Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007;30:1724–9.PubMedCrossRef
11.
go back to reference Lafarge JC, Naour N, Clement K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie. 2010;92:1580–6.PubMedCrossRef Lafarge JC, Naour N, Clement K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie. 2010;92:1580–6.PubMedCrossRef
12.
go back to reference Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol. 2008;3:1786–91.PubMedCrossRef Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol. 2008;3:1786–91.PubMedCrossRef
13.
go back to reference Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich). 2011;13:925–30.CrossRef Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich). 2011;13:925–30.CrossRef
16.
go back to reference American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34 Suppl 1:S62–9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34 Suppl 1:S62–9.
17.
go back to reference Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43:1016–22.PubMed Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43:1016–22.PubMed
21.
go back to reference Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004. Am J Kidney Dis. 2007;50:918–26.PubMedCrossRef Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004. Am J Kidney Dis. 2007;50:918–26.PubMedCrossRef
22.
go back to reference Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function—a review. Clin Chem Lab Med. 1999;37:389–95.PubMedCrossRef Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function—a review. Clin Chem Lab Med. 1999;37:389–95.PubMedCrossRef
23.
go back to reference Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens. 2006;15:270–5.PubMedCrossRef Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens. 2006;15:270–5.PubMedCrossRef
24.
go back to reference Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354–60.PubMedCrossRef Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354–60.PubMedCrossRef
25.
go back to reference Ristiniemi N, Lund J, Tertti R, et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2012;45:535–40.PubMedCrossRef Ristiniemi N, Lund J, Tertti R, et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2012;45:535–40.PubMedCrossRef
26.
go back to reference Harmoinen AP, Kouri TT, Wirta OR, et al. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol. 1999;52:363–70.PubMed Harmoinen AP, Kouri TT, Wirta OR, et al. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol. 1999;52:363–70.PubMed
27.
go back to reference Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard BC. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121:426–32.PubMedCrossRef Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard BC. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121:426–32.PubMedCrossRef
28.
go back to reference Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59:241–6.PubMedCrossRef Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59:241–6.PubMedCrossRef
29.
go back to reference Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118:1416.PubMedCrossRef Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118:1416.PubMedCrossRef
30.
go back to reference Leung-Tack J, Tavera C, Martinez J, Colle A. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation. 1990;14:247–58.PubMedCrossRef Leung-Tack J, Tavera C, Martinez J, Colle A. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation. 1990;14:247–58.PubMedCrossRef
31.
go back to reference Reffelmann T, Krebs A, Ittermann T, et al. Mild renal dysfunction as a non-traditional cardiovascular risk factor?-Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation. Atherosclerosis. 2010;211:660–6.PubMedCrossRef Reffelmann T, Krebs A, Ittermann T, et al. Mild renal dysfunction as a non-traditional cardiovascular risk factor?-Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation. Atherosclerosis. 2010;211:660–6.PubMedCrossRef
32.
go back to reference Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care. 2007;30:354–9.PubMedCrossRef Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care. 2007;30:354–9.PubMedCrossRef
33.
go back to reference Thorand B, Baumert J, Kolb H, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care. 2007;30:854–60.PubMedCrossRef Thorand B, Baumert J, Kolb H, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care. 2007;30:854–60.PubMedCrossRef
Metadata
Title
Serum cystatin C and prediabetes in non-obese US adults
Authors
Charumathi Sabanayagam
Tien Yin Wong
Jie Xiao
Anoop Shankar
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
European Journal of Epidemiology / Issue 4/2013
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-013-9781-3

Other articles of this Issue 4/2013

European Journal of Epidemiology 4/2013 Go to the issue